4/9
11:02 am
eyen
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update [Yahoo! Finance]
Medium
Report
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update [Yahoo! Finance]
4/8
07:18 am
eyen
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities [Yahoo! Finance]
High
Report
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities [Yahoo! Finance]
4/8
07:00 am
eyen
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
High
Report
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
4/3
07:09 am
eyen
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings [Yahoo! Finance]
Medium
Report
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings [Yahoo! Finance]
4/3
07:00 am
eyen
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
Medium
Report
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
3/27
11:44 am
eyen
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/19
08:56 am
eyen
Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
High
Report
Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/19
08:08 am
eyen
Eyenovia, Inc. (NASDAQ: EYEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
High
Report
Eyenovia, Inc. (NASDAQ: EYEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
3/18
04:20 pm
eyen
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/18
04:05 pm
eyen
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
High
Report
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
3/14
08:12 am
eyen
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 [Yahoo! Finance]
Medium
Report
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023 [Yahoo! Finance]
3/13
07:00 am
eyen
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
Medium
Report
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
3/11
07:35 am
eyen
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th [Yahoo! Finance]
Medium
Report
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th [Yahoo! Finance]
3/11
07:00 am
eyen
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
Medium
Report
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
3/6
08:40 am
eyen
Eyenovia, Inc. (NASDAQ: EYEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Eyenovia, Inc. (NASDAQ: EYEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
3/5
01:44 pm
eyen
Eyenovia falls despite FDA nod for pain therapy [Seeking Alpha]
Medium
Report
Eyenovia falls despite FDA nod for pain therapy [Seeking Alpha]
3/5
01:11 pm
eyen
Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation [Yahoo! Finance]
Medium
Report
Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation [Yahoo! Finance]
3/5
08:10 am
eyen
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery [Yahoo! Finance]
High
Report
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery [Yahoo! Finance]
3/5
08:00 am
eyen
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
High
Report
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
3/4
06:26 pm
eyen
UPDATE 1-US FDA approves Eyenovia's eye drug, Formosa Pharma says [Yahoo! Finance]
High
Report
UPDATE 1-US FDA approves Eyenovia's eye drug, Formosa Pharma says [Yahoo! Finance]
3/4
06:22 pm
eyen
US FDA approves Eyenovia's eye drug, Formosa Pharma says [Yahoo! Finance]
High
Report
US FDA approves Eyenovia's eye drug, Formosa Pharma says [Yahoo! Finance]
3/4
06:14 pm
eyen
US FDA approves Eyenovia's eye drug, Formosa Pharma says [Reuters]
High
Report
US FDA approves Eyenovia's eye drug, Formosa Pharma says [Reuters]
3/4
05:59 pm
eyen
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery [Yahoo! Finance]
High
Report
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery [Yahoo! Finance]
3/4
05:55 pm
eyen
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
High
Report
Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery
3/1
05:24 am
eyen
retail investors who own 56% along with institutions invested in Eyenovia, Inc. (NASDAQ:EYEN) saw increase in their holdings value last week [Yahoo! Finance]
High
Report
retail investors who own 56% along with institutions invested in Eyenovia, Inc. (NASDAQ:EYEN) saw increase in their holdings value last week [Yahoo! Finance]